申请人:Kyoto Pharmaceutical Industries, Ltd.
公开号:EP1857444A1
公开(公告)日:2007-11-21
The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.
本发明提供了一种具有优异 ACAT 抑制活性和/或抗氧化作用的四氢异喹啉化合物,特别是由式(I)(其中各符号如说明书所述)表示的新型化合物及其药学上可接受的盐。